Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 173

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 173
---
 |   |     | $    | (10,587,486 | ) |

The following table sets forth a summary of the net cash flow activity for the six months ended June 30, 2025 and 2024, respectively.:

| Net cash provided by (used in): |     | Six Months Ended June 30, 
 2025                      |             |   |     | 2024 |            |   |
|:--------------------------------|:----|:--------------------------|------------:|:--|:----|:-----|-----------:|:--|
| Operating activities            |     | $                         | (10,986,584 | ) |     | $    | (8,900,053 | ) |
| Investing activities            |     |                           |  (1,307,511 | ) |     |      |    (36,498 | ) |
| Financing activities            |     |                           |   8,149,741 |   |     |      | 17,582,805 |   |
| Net increase (decrease) in cash |     | $                         |  (4,144,354 | ) |     | $    |  8,646,254 |   |

**Operating Activities For the six months ended June 30, 2025, net cash used in operating activities was $11.0 million, which primarily consisted of a net loss of $16.2 million, a change in net operating assets and liabilities of $2.3 million, and non-cash charges of $2.9 million. The net non-cash charges were primarily related to depreciation and amortization expense of less than $0.1 million, and stock-based compensation of $2.8 million. The $2.3 million net change in operating assets and liabilities is primarily due to increases in accounts payable and accrued expenses of approximately $2.3 million due to timing of invoices and vendor payments, and an increase in current and non-current assets of approximately less than $0.1 million. For the six months ended June 30, 2024, net cash used in operating activities was $8.9 million, which primarily consisted of a net loss of $10.1 million and a change in net operating assets and liabilities of $0.3 million, and non-cash charges of $1.5 million. The net non-cash charges were primarily related, depreciation and amortization expense of less than $0.1 million, stock-based compensation